Beta-blockers in hypertension

Red Flags

Acute decompensated HF on a beta-blocker — do NOT abruptly discontinue; titrate down only after stabilisation; rebound effects possible^[1]
Severe asthma or COPD with bronchospasm on a non-cardioselective beta-blocker — switch to cardioselective (bisoprolol, nebivolol) or non-beta-blocker class^[1]
Symptomatic bradycardia (HR <50 with dizziness/syncope) on beta-blocker — reduce dose or switch class^[1]
Diabetes with frequent hypoglycaemia on non-cardioselective beta-blocker — masks adrenergic warning; prefer cardioselective or alternative^[1]

Compelling indications take precedence^[1]
Beta-blocker is FIRST-LINE in: post-MI, HFrEF, angina, atrial fibrillation rate control, migraine prophylaxis, essential tremor, thyrotoxicosis. Otherwise positions as 4th-line in stepped therapy after CCB, ACE-i/ARB, and thiazide diuretic
Avoid abrupt discontinuation^[1]
Taper over ≥2 weeks if discontinuing; abrupt withdrawal causes rebound hypertension, tachycardia, and (in CAD) ischaemia

Drug	Class	Adult	Paediatric	Notes
Bisoprolol^[1]	Cardioselective beta-blocker	2.5–10 mg PO once daily	—	Preferred when beta-blocker indicated; cardioselective minimises bronchospasm and metabolic effects
Metoprolol succinate (extended release)^[1]	Cardioselective beta-blocker	25–200 mg PO once daily	—	Alternative cardioselective option with strong HFrEF and post-MI evidence
Carvedilol^[1]	Non-selective beta-blocker with alpha-1 blockade	3.125–25 mg PO BD	—	Preferred in HFrEF, post-MI, and hypertension with diabetes (favourable metabolic profile)
Nebivolol^[1]	Cardioselective beta-blocker with NO-mediated vasodilation	2.5–10 mg PO once daily	—	Favourable metabolic profile; option in elderly, sexual dysfunction concerns, or HF with preserved EF

Bisoprolol^[1]

Cardioselective beta-blocker

Preferred when beta-blocker indicated; cardioselective minimises bronchospasm and metabolic effects

Metoprolol succinate (extended release)^[1]

Cardioselective beta-blocker

Alternative cardioselective option with strong HFrEF and post-MI evidence

Carvedilol^[1]

Non-selective beta-blocker with alpha-1 blockade

Preferred in HFrEF, post-MI, and hypertension with diabetes (favourable metabolic profile)

Nebivolol^[1]

Cardioselective beta-blocker with NO-mediated vasodilation

Favourable metabolic profile; option in elderly, sexual dysfunction concerns, or HF with preserved EF

Do not stop beta-blocker abruptly even if you feel well — can trigger rebound high BP and chest pain^[1]
If you develop wheezing, severe fatigue, or feel your heart rate slow significantly — contact your clinician for dose review^[1]
If you have diabetes, monitor blood glucose more frequently after starting a beta-blocker — they can mask hypoglycaemia warning signs^[1]

Symptomatic bradycardia or new heart block on beta-blockerCardiology for medication review and assessment for pacing^[1]
Resistant hypertension uncontrolled on triple therapy plus beta-blockerHypertension clinic for secondary cause workup^[1]
Severe asthma or COPD with bronchospasm on beta-blockerRespiratory and cardiology for class switch decision^[1]

Position on the contemporary role of beta-blockers in hypertension — first-line in compelling indications, fourth-line in uncomplicated hypertension.

1.Association of Physicians of India (API) Position Statement on Beta-Blockers in Hypertension (2024)